💊Mitsubishi Tanabe Pharma Corporation] Notice regarding acquisition of manufacturing and sales approval for Rupafin tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)  20170927

By JPN, Pharmaceutical

💊Mitsubishi Tanabe Pharma Corporation] Notice regarding acquisition of manufacturing and sales approval for Rupafin tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)

http://www.mt-pharma.co.jp/e/release/nr/2017/pdf/e_MTPC170927_2.pdf

More from tokioX :

  1. 💉To ALS patients in the world, we hope to deliver Japan-originated ALS treatment
  2. 💊Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology to Begin Collaborative Creation for Improving Efficiency of Clinical Trials for New Drug Development
  3. 💊Production of Liposome Drugs Utilizing Proprietary Technologies Including Anti-Cancer Agent FF-10832 New Manufacturing Facility to be Built at Toyama Chemical, a Fujifilm Company
  4. 💊Sumitomo Dainippon Pharma and Poxel Announce Strategic Partnership for Development and Commercialization of Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan, China and Eleven Other Asian Countries
  5. 💊Notice Regarding Implementation of New Drug Discovery Program “JOINUS” Using Drug Repositioning Compound Libraries by Astellas Pharma, Mitsubishi Tanabe Pharma and Daiichi Sankyo
  6. 🏹ITOCHU Announces Acquisition of Master License Rights to the CIMARRON Brand  20170927.
  7. 💊Bristol-Myers Squibb Company, Opivo® (generic name: niborumab), approved as Fda as a treatment for hepatocellular cancer patients with treatment history with sorafenib  20170927